Ingrid Hegbom Ekman joined Cambrex’s Karlskoga facility in 1994 and was responsible for the Technology Platform and was a responsible chemist for Cambrex Fine Chemicals. In 2002, she became Manager, R&D Process Development and Project Manager. Since 2006, she has been the Director of Research and Development for the facility. She has a Doctor of Technology from the Norwegian Institute of Technology, Department of Organic Chemistry (NTNU) and graduated in 1994.
Almost six years after N-nitrosodimethylamine (NDMA) contamination was first identified, the toxic short alkyl chain N-nitrosamine issue appears on the way to resolution. In contrast, N-Nitrosamine drug substance-related impurities (NDSRIs) are still a burgeoning issue with many new NDSRIs being reported on a weekly basis. This session will:
Head-Toxicology, Safety Assessment
Syngene International Ltd
Senior Applications Chemist
Ellutia
Senior Manager, Nitrosamine Testing and Analytical Technologies
TEVA Pharmaceuticals
Director of R&D
Cambrex
Analytical Specialist - External and Member of Nitrosamine Task Force
Novartis
Regulatory Compliance SME, Founding Expert Member and Nitrosamine Exchange Ambassador
© Copyright 2024 Russell Publishing Limited.
All Rights Reserved.
Registered address: Court Lodge, Hogtrough Hill, Brasted, Kent, TN16 1NU, United Kingdom
Company registration number: 2709148
+44 (0)1959 563 311
[email protected]
Access the latest news, articles, interviews and insights at European Pharmaceutical Review
